Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹8,940 Cr revenue.
COGS 31.1%, employees 22.2%.
“Also, you mentioned like you should see 150 basis point expansion in EBITDA margin.”
“So overall the company growth is around 10% to 11%. That is what is the overall broadly.”
“EBITDA margin improvement in spite of lower growth in the quarter, we have almost around 2.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.3%▲ | 10.5% |
| ROCE | 14.1%▲ | 13.8% |
| Net Margin | 9.5%▲ | 8.7% |
| EBITDA Margin | 18.6%▲ | 16.0% |
| Debt To Equity | 0.16x▼ | 0.21x |
| Rev Growth 3yr | 15.3%▲ | 5.8% |
| EPS Growth 3yr | -5.9%▼ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9,505 Cr +6.3% | ₹8,940 Cr +16.0% | ₹7,705 Cr +23.4% | ₹6,244 Cr +7.1% | ₹5,830 Cr +7.6% | ₹5,420 Cr +16.6% | ₹4,649 Cr +23.2% | ₹3,773 Cr |
| Other Income | ₹107 Cr +14.8% | ₹93 Cr -25.6% | ₹125 Cr -0.7% | ₹126 Cr +88.7% | ₹67 Cr +5.9% | ₹63 Cr -6.2% | ₹67 Cr +16.2% | ₹58 Cr |
| Total Income | ₹9,611 Cr +6.4% | ₹9,032 Cr +15.4% | ₹7,830 Cr +22.9% | ₹6,370 Cr +8.0% | ₹5,896 Cr +7.5% | ₹5,483 Cr +16.3% | ₹4,716 Cr +23.1% | ₹3,831 Cr |
| COGS | ₹2,839 Cr +2.2% | ₹2,779 Cr +7.9% | ₹2,576 Cr +11.7% | ₹2,307 Cr +14.5% | ₹2,015 Cr +16.6% | ₹1,728 Cr +5.1% | ₹1,644 Cr +32.6% | ₹1,240 Cr |
| ₹8,069 Cr +4.8% | ₹7,696 Cr +11.9% | ₹6,879 Cr +22.3% | ₹5,625 Cr +18.1% | ₹4,761 Cr +16.3% | ₹4,094 Cr +3.1% | ₹3,969 Cr +20.9% | ₹3,283 Cr | |
| Profit Before Tax | ₹1,296 Cr +14.6% | ₹1,131 Cr +34.2% | ₹843 Cr +13.1% | ₹745 Cr -34.4% | ₹1,136 Cr -18.2% | ₹1,389 Cr +86.0% | ₹747 Cr +36.2% | ₹548 Cr |
| Exceptional Items | (₹246 Cr) -19.8% | (₹205 Cr) -90.3% | (₹108 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹348 Cr +1.4% | ₹344 Cr +9.6% | ₹313 Cr +23.7% | ₹253 Cr +13.0% | ₹224 Cr -6.6% | ₹240 Cr +77.4% | ₹135 Cr +29.8% | ₹104 Cr | |
| Net Profit | ₹941 Cr +19.8% | ₹785 Cr +50.2% | ₹523 Cr +9.2% | ₹479 Cr -46.2% | ₹890 Cr -22.0% | ₹1,141 Cr +89.1% | ₹604 Cr +36.5% | ₹442 Cr |
| Profit (Owners) | ₹910 Cr +23.3% | ₹738 Cr +34.8% | ₹547 Cr +16.1% | ₹471 Cr -46.7% | ₹884 Cr -22.4% | ₹1,140 Cr +88.0% | ₹606 Cr +36.3% | ₹445 Cr |
| Minority Interest | ₹31 Cr -34.4% | ₹48 Cr ↑ Recovery | (₹24 Cr) ↓ Decline | ₹8 Cr +34.3% | ₹6 Cr +405.3% | ₹1 Cr ↑ Recovery | (₹3 Cr) -5.7% | (₹3 Cr) |
| Other Comprehensive Income | ₹8 Cr ↑ Recovery | (₹25 Cr) -159.8% | (₹9 Cr) ↓ Decline | ₹7 Cr +144.7% | ₹3 Cr ↑ Recovery | (₹0.40 Cr) ↓ Decline | ₹4 Cr ↑ Recovery | (₹4 Cr) |
| EPS | ₹35.86 | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 | ₹44.93 | ₹23.99 | ₹17.60 |
| Diluted Shares | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr |
| Profit Or Loss Of Associates | (₹7 Cr) -191.3% | (₹2 Cr) +63.6% | (₹6 Cr) +51.4% | (₹13 Cr) +38.8% | (₹21 Cr) -174.8% | (₹8 Cr) +1.4% | (₹8 Cr) -331.5% | (₹2 Cr) |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange about Transcript
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has informed the Exchange regarding 'Revised Link for q4FY26 Conference Call to be held today'.
IPCA Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 6 per equity share.
IPCA Laboratories Limited has informed the Exchange regarding re-appointment of Mr Mr. Prashant Godha as Executive Director of the company w.e.f. August 16, 2026.
IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
IPCA Laboratories Limited has informed the Exchange about Schedule of meet
IPCA Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
IPCA Laboratories Limited has informed the Exchange about Transcript
IPCA Laboratories Limited has informed the Exchange about Link of Recording
IPCA Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
IPCA Laboratories Limited has informed the Exchange about "Commencement of commercial production at Company's new manufacturing unit situated Village Hingani,District - Wardha"
IPCA Laboratories Limited has informed the Exchange about General Updates "